Form 8-K Edgewise Therapeutics, For: May 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/29/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- BioNTech ends colorectal cancer mRNA therapy trial early
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Pinterest CFO resigns, interim replacement named
Edgewise Therapeutics (EWTX) PT Raised to $52 at Wedbush
June 1, 2026 2:09 PM EDTWedbush analyst Laura Chico raised the price target on Edgewise Therapeutics (NASDAQ: EWTX) to $52.00 (from $46.00) while maintaining a Outperform rating.
The analyst comments "Remain Outperform rated on EWTX, new $52 target. EWTX reached a deal with Servier (not covered) to acquire all... More
